-
-
Medical Device Network (November 17, 2023) PostEra joins forces with Amgen for AI drug discovery
US-based biotech PostEra has partnered with Amgen for a multi-target collaboration in drug discovery. The companies will use PostEra’s artificial intelligence (AI) platform Proton and Amgen’s expertise in drug discovery to progress up to five small molecule programs. Proton platform is an end-to-end machine learning platform to close the design-make-test cycle of medicinal chemistry, which can often be time-consuming and expensive.
Nature (November 16, 2023) How wild monkeys ‘laundered’ for science could undermine research
Demand is fueling an illegal trade. But smuggled monkeys carry diseases that can disrupt experiments and lead to unreliable data.
News Medical & Life Sciences (November 15, 2023) Senolytics show promise in combating brain aging and COVID-19 neuropathology
In a recent study published in the journal Nature Aging, an international team of researchers observed that senolytics can alleviate physiologic brain aging and coronavirus disease 2019 (COVID-19) neuropathology. Senolytics are a class of drugs that selectively target and eliminate senescent cells, which are cells that have stopped dividing and contribute to aging and age-related diseases.
BioPharm (November 14, 2023) Charles River Laboratories and Aitia Partner on Neurodegenerative Disease and Oncology Drug Development
Aitia, a drug development and drug discovery technology company, announced on Nov. 13, 2023 a partnership with Charles River Laboratories, a contract development and manufacturing organization. Under the partnership, Aitia will be given access to Logica, Charles River’s artificial intelligence (AI)-powered drug solution platform. Aitia will use Logica across its portfolio of novel drug targets to create potential treatments for neurological indications, including Alzheimer’s, Parkinson’s, and Huntington’s diseases, as well as a variety of cancer treatments. The partnership also includes co-development of patient-derived xenograft (PDX) Digital Twins for in-vivo oncology research.
Bloomberg (November 13, 2023) Race for First Drug Discovered by AI Nears Key Milestone
The global push to use artificial intelligence to find new medicines faces a crucial test as one front-runner starts approaching late-stage trials for a drug discovered by algorithms. Insilico Medicine — which has headquarters in Hong Kong and New York — used AI to develop an experimental drug for the incurable lung disease idiopathic pulmonary fibrosis. The treatment is in mid-stage trials in the US and China with some results expected early 2025. The results of Insilico’s trials are being closely watched in the drug industry because the company used AI to identify a new approach to fight against the deadly disease and produce a novel molecule to treat it. UK-based researcher Deep Pharma Intelligence says that the Insilico therapy is the global industry’s first fully AI-based preclinical candidate.
News Medical & Life Sciences (November 13, 2023) Crown Bioscience launches large-scale organoid panel screening platform for accelerated preclinical oncology drug discovery
Crown Bioscience, a global contract research organization (CRO) and JSR Life Sciences company, today announced the launch of its ground-breaking service offering, OrganoidXploreTM. This large-scale organoid panel screening platform promises robust, reproducible, and clinically relevant output at record speed, accelerating preclinical oncology drug discovery by empowering researchers and reshaping the landscape of cancer treatment development.
PETA (November 9, 2023) Progress! We’re Changing the Industry—and Charles River Labs Is Feeling the Heat
Charles River Laboratories, a top importer of monkeys into the U.S. for laboratory experimentation, reported during its third-quarter earnings call that it estimates it will use a whopping 25% fewer of them globally in 2023 than in 2022. And it’s not because there’s a monkey shortage. Charles River CEO James Foster said the dramatic decrease is because “the industry is changing.” Translation: The pharmaceutical industry is pivoting to non-animal testing methods.
BioITWorld (November 8, 2023) Big Pharma, Moderna on An AI-Empowered Era of Drug Discovery
At a panel early last month at the HLTH 2023 event, speakers from Takeda, Bristol Myers Squibb, Moderna and Eli Lilly discussed what moderator Jessica Federer, former Bayer Chief Digital Officer, called a drug discovery renaissance.
Pharmacy Times (November 7, 2023) How AI Is Helping Researchers Fight Superbugs Faster Than Ever Before
In an industry where it can take 10 to 12 years for a novel therapeutic—that pathogens haven’t yet met—to be approved for use, tiny pathogens become a big problem very fast. Artificial intelligence (AI) has already proven to exponentially speed up the work done by researchers without sacrificing, and in many cases increasing, accuracy. If applied correctly to drug development, AI could significantly speed up drug discovery and development, and help researchers end the treatment-resistant infection crisis before it’s too late.
Technology Networks (November 6, 2023) Extracting Meaningful Data With Advances in High-Throughput Drug Discovery Approaches
The journey of finding a new drug is a tedious process requiring enormous effort and funds. The process usually starts by understanding the disease mechanisms and identifying suitable “targets”. Next is the identification of “hits”, which are molecules that elicit a desired activity towards the target in a screening activity. From hits that show a promising therapeutic activity, “leads”, or compounds of interest, are selected for further optimization. High-throughput screening (HTS), virtual screening and fragment-based drug discovery are some popular screening approaches used to identify hits. This article focuses on the use of HTS approaches in drug discovery and discuss the latest developments in this area.
SciTechDaily (November 6, 2023) Nanowired Cardiac Organoids – New Technology Could Revolutionize Recovery After Heart Attack
A team of bioengineers and clinician-scientists at the Medical University of South Carolina (MUSC) and Clemson University (CU) are on the cusp of a revolutionary approach that could change the landscape of cardiac care by repairing damaged heart tissue. They reported their promising preclinical findings in the August issue of Science Advances. The team is led by Ying Mei, Ph.D., who has a joint appointment at CU and MUSC and is part of the CU-MUSC program in Bioengineering. Ryan Barrs, a doctoral candidate in the joint program, is one of the lead authors of the article. “The damage left behind by heart attacks is usually thought to be permanent and can require heart transplants, which are in short supply,” said Barrs. “Here, we developed electrically conductive ‘mini-hearts’ that could be injected into injured heart muscle to restore its pumping function.”
Fierce Pharma (November 6, 2023) House lawmakers launch probe into FDA’s response to nationwide drug shortages
As shortages of drugs like amoxicillin, penicillin, Adderall and certain chemotherapies continue to confound doctors and patients in the U.S., two high-ranking Republican lawmakers are pressing the FDA for answers. In a letter (PDF) to FDA Commissioner Robert Califf, M.D., the chairman of the House Committee on Oversight and Accountability, James Comer, R-Kentucky, and Lisa McClain, R-Michigan, chairwoman of the Subcommittee on Health Care and Financial Services, requested documents and a staff-level briefing to parse through the agency’s shortage mitigation strategies.
Pharmacy Times (November 6, 2023) AI in Biomedical Research Is Revolutionizing Drug Development, Clinical Innovation
Artificial intelligence (AI) is on the verge of transforming how physicians and scientists conduct biomedical research. From hunting for new treatments to running clinical trials, AI is starting to reshape every step of the scientific process. Some experts think we’re headed for a world where AI will take over and replace researchers, but the reality will likely be more human-focused than that. AI is a tool—a powerful one, but still just a tool. It needs human guidance to function optimally and ethically. However, it remains valuable to examine how exactly researchers are beginning to use AI as their lab partner.
-
- You must be logged in to reply to this topic.